Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
AMLo Biosciences logo — Developing an innovative prognostic test for early-stage cut...

AMLo Biosciences

Developing an innovative prognostic test for early-stage cutaneous melanoma

Founded 2017 United Kingdom Newcastle Upon Tyne, United Kingdom 22 employees Series Unknown Total: $2.45M Biotechnology

General Information

Company Name AMLo Biosciences
Founded Year 2017
Location United Kingdom Newcastle Upon Tyne, United Kingdom +1
Employees 22
Industries Biotechnology
Funding Stage Series Unknown
Social

Get notified when AMLo Biosciences moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About AMLo Biosciences

AMLo Biosciences is a biotechnology startup founded in 2017 and based in the United Kingdom. The company's mission is to develop an innovative prognostic test for early-stage cutaneous melanoma, known as AMBLor®, which aims to better identify patients’ true risk of disease progression. This test is designed to seamlessly integrate into current diagnostic practices, making it user-friendly for healthcare professionals. The startup has received a noteworthy £2.45M Venture Round investment on 21 April 2022 from a group of prominent investors including Northstar Ventures, Future Planet Capital, Esperante Ventures, and Ascension Life Fund. This investment is a strong indicator of confidence in AMLo Biosciences' approach and potential impact in the biotech industry. With a team boasting a globally recognized research track record in the melanoma field, including proficiency in translational biomarkers, drug discovery, and biotech company building, AMLo Biosciences has the expertise and experience to drive the development and successful implementation of their prognostic test. Overall, AMLo Biosciences shows promise in revolutionizing early-stage melanoma prognosis and has attracted significant investment interest from reputable venture capital firms.

Taxonomy: Biotech, Melanoma, Prognostic Test, Early-stage, Diagnostic Practice, Translational Biomarkers, Drug Discovery, Research, Start-up, Investment, Medical Innovation

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round •••••• 4
Investor Investor Investor
•••• •••• 		21 Apr 2022
Seed Round •••••• 1
Investor
01 Nov 2020
Seed Round •••••• 1
Investor
24 Aug 2018

AMLo Biosciences Alternatives & Competitors

AMLo Biosciences vs
Castle Biosciences, Inc.
Castle Biosciences, Inc. United States

Improving health through innovative tests that guide patient care

Post Ipo Equity
744 employees
Biotechnology, Health Care
AMLo Biosciences vs
MLA Diagnostics
MLA Diagnostics The Netherlands

Developing a revolutionary prognostic test for early stage melanoma

Series Unknown
9 employees
Health Care, Medical Devices
AMLo Biosciences vs
Aura Biosciences
Aura Biosciences United States

Aura Biosciences is a clinical-stage biotechnology company developing virus-like drug conjugates (VD...

Post Ipo Equity
113 employees
Biotechnology, Health Care

FAQ About AMLo Biosciences

Developing an innovative prognostic test for early-stage cutaneous melanoma
AMLo Biosciences was founded in 2017.
AMLo Biosciences is headquartered in Newcastle Upon Tyne, United Kingdom.
AMLo Biosciences operates in the following industries: Biotechnology.
AMLo Biosciences has approximately 22 employees.
AMLo Biosciences has completed 3 funding rounds, raising a total of $2.45M. The latest funding stage is Series Unknown.
Top alternatives and competitors to AMLo Biosciences include Castle Biosciences, Inc., MLA Diagnostics, Aura Biosciences, Geneseq Biosciences, Veramarx, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
AMLo Biosciences and Castle Biosciences, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors AMLo Biosciences and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy